A comprehensive view of Oral Medicines/Supplements. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

European Medicines Agency accepts GSK's marketing authorization application for momelotinib for the treatment of myelofibrosis, a type of bone marrow cancer; myelofibrosis affects approximately 20,000 patients in the US

Sorrento Therapeutics reports its STI-1558 experimental oral COVID-19 drug shows initial signs of efficacy in two early-stage studies; in one study treatment reduced viral RNA load by the third day

Nestle mulls options for peanut allergy drug Palforzia after slow adoption by patients, healthcare professionals; Palforzia is only oral immunotherapy approved by FDA to reduce allergic reactions to peanuts

Kyowa Kirin divests 13 mature brands to Grunenthal in deal worth US$83.0M, plus royalties; products include Abstral fentanyl sublingual tablets, PecFent fentanyl nasal spray, Moventig naloxegol, Adcal-D3 calcium and vitamin D3 for osteoporosis

Health Canada approves Bristol Myers Squibb’s Sotyktu deucravacitinib tablets to treat severe plaque psoriasis in adults; Psoriasis is a chronic inflammatory condition that affects nearly a million Canadians

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count